Taxonomy

The CMTA Appoints Professor Charlotte Sumner, M.D., to its Scientific Advisory Board

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth

Read More

CMTA Awards Over Half a Million Dollars to Fuel Research in Demyelinating Forms of CMT

Multisite and multiyear collaborative project led by a team of

Read More

ToolGen CMT1A Treatment Receives Orphan Drug Designation

CMTA Alliance Partner ToolGen announced December 18, 2023 that it

Read More

Pharnext Announces Disappointing Results for CMT1A Drug Trial PXT-3003

Published: December 11, 2023 French biopharmaceutical company Pharnext SA announced

Read More

Novartis Secures $1.3B Deal for CMT Treatment CKD-510

Novartis is making significant strides in the field of Charcot-Marie-Tooth

Read More

Therapeutic Inactivation of CMT2 Disease Alleles with CRISPR

New technologies in gene editing such as CRISPR/Cas9 present a

Read More

CMTA Announces Participation in Seed Extension Round for Armatus Bio for Novel CMT1A Gene Therapy

First Investment from CMTA’s New Venture Philanthropy Arm The Charcot-Marie-Tooth

Read More

CMTA Awards $225,483 for Study On Using ASOs to Treat CMT2E

The Charcot-Marie-Tooth Association (CMTA) Board of Directors announced Sept. 28

Read More

Muscular Dystrophy Association and Charcot-Marie-Tooth Association Announce Collaborative Non-Viral Gene Therapy Research Grant

New York, NY – September 12, 2023 — The Muscular

Read More

CMTA Hails Novartis Acquisition of DTx Pharma And Its CMT1A Therapeutic Program

The Charcot-Marie-Tooth Association July 17 hailed the news that global

Read More